These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885 [TBL] [Abstract][Full Text] [Related]
4. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2]. Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341 [TBL] [Abstract][Full Text] [Related]
5. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674 [TBL] [Abstract][Full Text] [Related]
6. Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313 [TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283 [TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD; Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999 [TBL] [Abstract][Full Text] [Related]
12. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Kujawski LA; Talpaz M Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986 [TBL] [Abstract][Full Text] [Related]
13. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553 [TBL] [Abstract][Full Text] [Related]
14. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of chronic myeloid leukemia with interferon-alpha]. Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958 [TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029 [TBL] [Abstract][Full Text] [Related]
17. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603 [TBL] [Abstract][Full Text] [Related]
18. Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients. Tanaka H; Tanaka K; Oguma N; Ito K; Ito T; Kyo T; Dohy H; Kimura A Cancer Genet Cytogenet; 2004 Sep; 153(2):133-43. PubMed ID: 15350303 [TBL] [Abstract][Full Text] [Related]
19. Interferon-alfa for chronic myeloid leukemia. Baccarani M; Russo D; Rosti G; Martinelli G Semin Hematol; 2003 Jan; 40(1):22-33. PubMed ID: 12563609 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]